Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2Completed 2Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Acrocephalosyndactylia 4Cholangiocarcinoma 2Carcinoma, Transitional Cell 2Urinary Bladder Neoplasms 1Solid Tumor 1Recurrence 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms, Unknown Primary 1Neoplasms 1Myeloproliferative Disorders 1Fibroblast Growth Factors (FGFs)/Fibroblast Growth Factor Receptors (FGFRs) Genetic Aberration Gastric Cancer, INCB054828, Paclitaxel 1Eosinophilia 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 25Gemcitabine 21Nivolumab 17Cisplatin 17atezolizumab 14Carboplatin 11avelumab 9vinflunine 7Ipilimumab 7Paclitaxel 6Docetaxel 5enfortumab vedotin 4cabazitaxel 4Pemetrexed 4Mitomycin 4cabozantinib 3Taxes 3Rogaratinib 3Magnetic Resonance Spectroscopy 3Injections 3Albumin-Bound Paclitaxel 3tremelimumab 2sacituzumab govitecan 2pemigatinib 2niraparib 2lenvatinib 2bempegaldesleukin 2apatorsen 2XRP6258 2Vitamin D 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Carcinoma, Transitional Cell × pemigatinib × Clear all
NCT03914794 2025-10-03

A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
30 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT02872714 2025-08-14

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)

Incyte Corporation

Phase 2 Completed
263 enrolled 20 charts
Genitourinary

Acrocephalosyndactylia, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡